Dr Lal PathLabs To Buy 70% Stake In SN Genelab For Up To ₹168 Crore
Add Preferred News Source
Dr Lal PathLabs has approved the acquisition of a 70% stake in SN Genelab for up to ₹168 crore, including a performance-linked earn-out of ₹31.5 crore. SN Genelab, which reported ₹57.96 crore turnover in FY26, will become a subsidiary as Dr Lal PathLabs expands its genomics and advanced diagnostics portfolio.
Dr Lal PathLabs has approved the acquisition of a 70% stake in SN Genelab for up to ₹168 crore, expanding the diagnostic services provider’s presence in genomics and advanced diagnostic testing.
SN Genelab, which provides genomics diagnostic services, will become a subsidiary of Dr Lal PathLabs after the transaction. The acquisition is aimed at strengthening the company’s genomics capabilities and expanding its portfolio of advanced diagnostic services. SN Genelab reported turnover of ₹57.96 crore in FY26, up from ₹53.36 crore in FY25 and ₹43.27 crore in FY24.
The acquisition was approved by the Dr Lal PathLabs board on Thursday, September 24. The transaction involves a cash purchase of the 70% stake from SN Genelab’s existing shareholders and does not require government or regulatory approvals. Dr Lal PathLabs shares closed at ₹1,958.80 on the BSE on Thursday, up 1.88%, putting the stock in focus ahead of Friday’s trading session.
Dr Lal PathLabs expands genomics portfolio
SN Genelab is a Gujarat-based diagnostics company operating in the genomics segment. Its services include genomics diagnostic testing, an area that Dr Lal PathLabs said will add to its existing portfolio of advanced diagnostic capabilities.
The acquisition will give Dr Lal PathLabs access to SN Genelab’s genomics capabilities while expanding its presence in specialised diagnostic testing. The company has been building its diagnostic network and portfolio as demand for more specialised testing increases.
SN Genelab was incorporated on December 16, 2013. The company reported revenue of ₹57.96 crore in FY26, compared with ₹53.36 crore in FY25 and ₹43.27 crore in FY24.
SN Genelab deal structure
Dr Lal PathLabs will acquire 70% of SN Genelab from its existing shareholders. The upfront consideration will be paid in cash, while the deal also includes a performance-linked earn-out of up to ₹31.5 crore.
The company said the transaction is not a related-party transaction. It also does not require any government or regulatory approval, according to the disclosure.
The acquisition is expected to close by November 30, subject to the completion of the stated conditions.
Dr Lal PathLabs shares in focus on September 25
Dr Lal PathLabs shares ended Thursday’s session at ₹1,958.80 on the BSE, gaining ₹36.20, or 1.88%.
With the acquisition announced after the board meeting on Thursday, the stock will be in focus when trading resumes on September 25. Investors will track the market response to the ₹168 crore acquisition, the addition of genomics capabilities and the financial performance of SN Genelab.
Also Read - SEBI Clears Fourth Round Of Settlement For Illiquid Stock Options Cases, Sets Settlement Amount
This article is for informational purposes only and should not be considered investment advice from Kotak Neo. For compliance T&C and disclaimers, Visit www.kotakneo.com/disclaimer
Rochelle Britto has spent 8+ years decoding India's markets, businesses, and consumer economy, reporting for ET Prime and Times Internet along the way, covering the stories behind the numbers.
A Mumbai native and perpetual planner of the next holiday, she stays far, far away from the eternal question, “Where are we going next?” When she's not chasing headlines, she's chasing new cultures, open roads, and a bit of quiet in nature.
Right Tools, Rich Insights
